Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €44.45 EUR
Change Today +3.56 / 8.71%
Volume 30.0
SG7 On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 1:40 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

sage therapeutics inc (SG7) Snapshot

Open
€41.63
Previous Close
€40.88
Day High
€44.87
Day Low
€41.00
52 Week High
03/20/15 - €51.02
52 Week Low
07/29/14 - €18.70
Market Cap
1.1B
Average Volume 10 Days
43.7
EPS TTM
--
Shares Outstanding
25.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SAGE THERAPEUTICS INC (SG7)

sage therapeutics inc (SG7) Related Businessweek News

No Related Businessweek News Found

sage therapeutics inc (SG7) Details

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat life-threatening and rare central nervous system disorders. The company’s lead product candidate includes SAGE-547, an intravenous (IV) agent that is in Phase I/II clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE). Its pipeline also includes second-generation molecules, such as SAGE-217, an oral therapy for orphan genetic epilepsies; and SAGE-689, an adjunctive intravenous second-line therapy for the treatment of refractory status epilepticus. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is based in Cambridge, Massachusetts.

31 Employees
Last Reported Date: 03/17/15
Founded in 2010

sage therapeutics inc (SG7) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $153.0K
Chief Medical Officer
Total Annual Compensation: $149.0K
Chief Scientific Officer
Total Annual Compensation: $302.5K
Compensation as of Fiscal Year 2013.

sage therapeutics inc (SG7) Key Developments

Sage Therapeutics, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2014

Sage Therapeutics, Inc. reported consolidated earnings results for the year ended December 31, 2014. For the year, the company reported loss from operations of $33,810,000 compared to $18,279,000 a year ago. Net loss and comprehensive loss was $33,811,000 compared to $18,281,000 a year ago. Net loss attributable to common stockholders was $36,105,000 or $1.67 per basic and diluted share compared to $18,288,000 or $12.26 per basic and diluted share a year ago.

Sage Therapeutics, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015

Sage Therapeutics, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015 . Venue: JW Marriott Essex House, 160 Central Park South, b/w 6th & 7th Avenue, New York, New York, United States.

SAGE Therapeutics Appoints New Vice Presidents to Lead Key Organizational Functions

SAGE Therapeutics announced the appointment of Amy Schacterle, Ph.D., as vice president of regulatory affairs and quality assurance and Erin Lanciani as vice president of human resources. Dr. Schacterle brings to SAGE extensive expertise in regulatory affairs and quality assurance, with 22 years of experience in the biotech and life science industries, including 15 years in executive management. She most recently served as vice president, regulatory affairs at Sunovion Pharmaceuticals (previously Sepracor), where she worked for 10 years, also serving as executive director and senior director of regulatory affairs. Erin Lanciani brings more than 20 years of experience in developing human resources strategies and programs to the company. Before joining SAGE, Ms. Lanciani served as executive director, human resources, global commercialization at Bristol-Myers Squibb, joining the company through its October 2007 acquisition of Adnexus, where she was the vice president of human resources and a member of the executive leadership team.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SG7:GR €44.45 EUR +3.56

SG7 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SG7.
View Industry Companies
 

Industry Analysis

SG7

Industry Average

Valuation SG7 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 10.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAGE THERAPEUTICS INC, please visit www.sagerx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.